Feb 14, 2020 - In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
Feb 07, 2020 - The technique itself appears to be safe and effective in humans.
Feb 07, 2020 - This gene-editing biotech company rewarded those who invested in its cutting-edge technology.
Jan 31, 2020 - Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Jan 28, 2020 - On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
Jan 20, 2020 - These stocks could thump the broader markets this year.
Dec 22, 2019 - More pipeline activity than ever before could usher in a big boom for CRISPR gene-editing stocks next year.
Dec 19, 2019 - An early-stage start-up with an improved version of CRISPR gene editing filed to go public. Investors may want to keep an eye on it.
Dec 04, 2019 - The rare-disease specialist is putting together a respectable end-of-year run.
Nov 29, 2019 - The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.